Codi QR

Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

Abstract Circulating tumor DNA (ctDNA) is a promising biomarker in early hormone receptor (HR) + , HER2-negative breast cancer. We assessed ctDNA with the RaDaR assay in NeoRHEA (NCT03065621), a single-arm, phase II neoadjuvant palbociclib plus endocrine therapy trial over 4 months (4 × 28-day cycle...

Descripció completa

Guardat en:
Autors principals: Alexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, Christodoulos Pipinikas, Amber Chevalier, Nathan Campbell, Mariana Brandão, Lieveke Ameye, Marianne Paesmans, Tatiana Besse, Francoise Rothe, Laurence Buisseret, Donatienne Taylor, Patrick Neven, Christos Sotiriou, Francois P. Duhoux, Peter Vuylsteke, Michail Ignatiadis
Format: Artigo
Idioma:Inglês
Publicat: Nature Portfolio 2025-12-01
Col·lecció:npj Breast Cancer
Accés en línia:https://doi.org/10.1038/s41523-025-00852-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars